APOLLO Trial Establishes New Standard for High-Risk Acute Promyelocytic Leukemia Treatment

The European intergroup APOLLO phase III trial has established a new treatment paradigm for high-risk acute promyelocytic leukemia (APL), demonstrating that an all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) combination significantly outperforms standard chemotherapy-based regimens. The multicenter study, published in the Journal of Clinical Oncology, showed superior efficacy and markedly reduced toxicity with the ATO-based approach.

Trial Design and Patient Population

The APOLLO trial randomized 133 patients with newly diagnosed high-risk APL between two treatment arms. The experimental ATRA-ATO group (n=68) received ATO at 0.15 mg/kg once daily and ATRA at 45 mg/m² twice daily until complete remission, with two doses of idarubicin at 12 mg/m² on days 1 and 3, followed by four ATRA-ATO consolidation cycles. The control ATRA-CHT group (n=65) received standard induction with ATRA at 45 mg/m² twice daily and idarubicin at 12 mg/m² once daily on days 1, 3, 5, and 7, followed by three cycles of chemotherapy-based consolidation and 2 years of maintenance therapy.

Enrollment began in June 2016 but was discontinued prematurely in August 2022 due to slow accrual during the COVID-19 pandemic. The primary endpoint was 2-year event-free survival.

Superior Efficacy Outcomes

After a median follow-up of 37 months (range 1.7-88.6 months), the ATRA-ATO regimen demonstrated compelling efficacy advantages. Two-year event-free survival reached 88% in the ATRA-ATO group versus 71% in the ATRA-CHT group, representing a hazard ratio of 0.4 (95% CI 0.17-0.92, P = .02).

The molecular relapse data proved particularly striking. At a median of 7.8 and 12.1 months from achievement of complete remission, molecular relapse occurred in only one patient (1.5%) in the ATRA-ATO group compared to eight patients (12.3%) in the ATRA-CHT group (P = .014). The 2-year cumulative incidence of relapse was 1.8% versus 17% (P = .008), demonstrating the durability of responses with the ATO-based regimen.

Overall survival trends favored the ATRA-ATO approach, with 2-year rates of 93% versus 87% in the chemotherapy arm, though this difference did not reach statistical significance (HR 0.6, 95% CI 0.2-1.8, P = .36).

Improved Safety Profile

The safety advantages of the ATRA-ATO regimen proved equally compelling. Serious adverse events suspected to be treatment-related occurred in only 7 patients (10%) in the ATRA-ATO group compared to 24 patients (37%) in the ATRA-CHT group (P < .01).

In the ATRA-ATO group, serious adverse events included acute kidney injury, acute pulmonary edema, capillary leak syndrome, differentiation syndrome, and myocarditis, with one patient experiencing each event. The ATRA-CHT group showed a different toxicity profile, with febrile neutropenia being most common (n=9) followed by differentiation syndrome (n=5).

Clinical Implications

The APOLLO trial results provide definitive evidence supporting the adoption of ATRA-ATO combination therapy as the new standard of care for newly diagnosed high-risk APL patients. As the investigators concluded, "The results of the APOLLO trial support the use of ATO and ATRA for the treatment of newly diagnosed patients with high-risk acute promyelocytic leukemia."

The study's findings represent a significant advancement in APL treatment, offering patients both improved survival outcomes and reduced treatment-related toxicity. The dramatic reduction in molecular relapse rates suggests that the ATRA-ATO regimen may provide more durable remissions, potentially reducing the long-term burden of disease recurrence in this patient population.